Clinical trials: Diabetes, Type 1
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
The purpose of the study is to evaluate the clinical effects of the investigational drug, SB-509, in subjects with diabetic neuropathy.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy
- Trial name
- NCT01079325
- Testing
- SB-509, Saline
- Where
- 31 sites in United States
- Volunteers
- 170 people
- Sponsor
- Sangamo Therapeutics
Diabetes, Diabetes Mellitus, Type 1
Observational Study of NovoPen® 4 on Treatment Satisfaction of Insulin Therapy in Type 1 or Type 2 Subjects With Diabetes Mellitus
This study is conducted in Asia. The aim of this observational study is to evaluate subjects' treatment satisfaction and to evaluate subjects' preference of pen device and the incidence of clinical technical complains while using…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
- Trial name
- NCT00806858
- Testing
- NovoPen® 4
- Where
- China
- Volunteers
- 526 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Comparison of NovoFine® Needles (4 mm vs. 6 mm)
This trial is conducted in Europe. The aim of this investigation is to explore the safety of a 4 mm needle compared to a 6 mm needle when injected in children and lean adults with diabetes.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
- Trial name
- NCT00343343
- Testing
- NovoFine® needle 6 mm, NovoFine® needle 4 mm
- Where
- 2 sites in Denmark
- Volunteers
- 62 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Examining the Long-term Safety of Insulin Aspart When Used as a Part of the Treatment for Type 1 Diabetes
This trial is conducted in Europe and Asia. The aim of this clinical trial is to investigate the long-term safety of insulin aspart in the management of type 1 diabetes. An extension to the ANA/DCD/065 trial
- Trial name
- NCT00832182
- Testing
- insulin aspart, insulin NPH
- Where
- 10 sites in Croatia, Czechia and 3 more
- Volunteers
- 75 people
- Sponsor
- Novo Nordisk A/S
Type1 Diabetes Mellitus
Insulet Artificial Pancreas Free-Living IDE3
Subjects will undergo a 7±1 day outpatient, standard therapy phase during which sensor and insulin data will be collected. Subjects or their caregivers will manage their diabetes at home per their usual routine using the study…
- Trial name
- NCT03216460
- Testing
- Insulet automated glucose control system
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Insulet Corporation
Diabetes Mellitus, Type 1
A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue
LY2605541 is an investigational drug being developed for the treatment of diabetes mellitus. This study is designed to understand how the body handles the investigational drug, and to measure the quantity of LY2605541 in fat…
- Trial name
- NCT02109029
- Testing
- Insulin Peglispro, Human Insulin
- Where
- Austria
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
IgA Nephropathy, CKD Associated With Type 1 Diabetes
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
This multi-center, open-label Phase 2 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with the following rare chronic kidney diseases (CKD): CKD associated with type 1 diabetes…
- Conditions
- IgA Nephropathy, CKD Associated With Type 1 Diabetes, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney
- Trial name
- PHOENIX (NCT03366337)
- Testing
- Bardoxolone methyl capsules
- Where
- 30 sites in United States
- Volunteers
- 103 people
- Sponsor
- Biogen
Diabetic Retinopathy
Computer-based Screening for Diabetic Retinopathy
The study is an Observational, Phase 0 designed to establish that the risk for diabetic retinopathy assigned by the RiskAnalyzer improves the reading accuracy and consistency of any reader and it decreases the inter-reader…
- Trial name
- NCT01614327
- Where
- 2 sites in United States
- Volunteers
- 19,199 people
- Sponsor
- VisionQuest Biomedical LLC
Diabetes Mellitus, Type I, IDDM
SteadiSet™ Pilot Study (SteP Study)
This study will evaluate the safety and effectiveness of how well blood glucose is managed when a participate wears the investigational SteadiSet™ Infusion Set (SteadiSet device) for up to 14 days post-insertion when compared to…
- Conditions
- Diabetes Mellitus, Type I, IDDM, Diabetes Mellitus, Insulin-Dependent, 1, Type 1 Diabetes
- Trial name
- NCT04591925
- Testing
- Control Device insulin infusion devcie, Investigative insulin infusion devcie
- Where
- Austria
- Volunteers
- 13 people
- Sponsor
- Capillary Biomedical, Inc.
Type1 Diabetes Mellitus
A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus
Primary Objective: To demonstrate bioequivalence between insulin glulisine given as 300 Units/mL test formulation and insulin glulisine 100 Units/mL reference formulation after a single subcutaneous (SC) dose.
- Trial name
- NCT02910518
- Testing
- Insulin glulisine (U300), Insulin glulisine, Insulin aspart
- Where
- Germany
- Volunteers
- 44 people
- Sponsor
- Sanofi
Solid Tumor, Unresectable or Metastatic Melanoma
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
To obtain evidence of antitumor effect of CX-072 in combination with anticancer therapy in adult patients with solid tumor based upon overall response rate by Response Evaluation Criteria in Solid Tumors (RECIST)
- Trial name
- NCT03993379
- Testing
- CX-072, Ipilimumab
- Where
- 27 sites in United States, Australia and 3 more
- Volunteers
- 3 people
- Sponsor
- CytomX Therapeutics
Obesity and Obesity-related Medical Conditions
A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes
This study is designed to test how well the combination of MET233 with MET097 works to treat individuals with obesity or overweight with or without diabetes.
- Trial name
- NCT06924320
- Testing
- MET233 and MET097, MET097
- Where
- United States
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Pfizer
Type 1 Diabetes, Kidney Transplant
An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant
This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.
- Trial name
- NCT06832410
- Testing
- Biological/Vaccine
- Where
- 7 sites in United States, Canada and 1 more
- Volunteers
- 10 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Advanced Sarcoma, Metastatic Sarcoma
YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma
This is a multicenter, open label, Phase 1/2 study of YH001 initially given in combination with envafolimab, and then given in combination with envafolimab plus doxorubicin in patients with advanced or metastatic sarcoma…
- Conditions
- Advanced Sarcoma, Metastatic Sarcoma, Soft Tissue Sarcoma
- Trial name
- NCT05448820
- Testing
- YH001, Envafolimab, Doxorubicin
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Type 1 Diabetes
Clinical Application of Stem Cell Educator Therapy in Type 1 Diabetes
Type 1 diabetes (T1D) is a T cell-mediated autoimmune disease that causes a deficit of pancreatic islet beta cells. Millions of individuals worldwide have T1D, and incidence increases annually.
- Trial name
- NCT04011020
- Testing
- Stem Cell Educator therapy
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Yong Zhao, MD, PhD
Type 1 Diabetes Mellitus
Prepivotal Omnipod Horizon™ Automated Glucose Control System
Subjects will undergo a 14-day outpatient, standard therapy phase during which sensor and insulin data will be collected. This will be followed by a 14-day hybrid closed-loop phase conducted in both a hotel/rental house setting…
- Trial name
- NCT04176731
- Testing
- Omnipod Horizon™ Automated Glucose Control System
- Where
- 6 sites in United States
- Volunteers
- 36 people
- Sponsor
- Insulet Corporation
Diabetes, Diabetes Mellitus, Type 1
The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate if liraglutide adjunct to insulin treatment changes the glucagon response during hypoglycaemia in subjects with type 1 diabetes compared with conventional…
- Trial name
- NCT01536665
- Testing
- liraglutide
- Where
- Austria
- Volunteers
- 45 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients
The study is a prospective, randomized, 52-week double-blind, placebo-controlled, multicenter trial in subjects with Type 1 diabetes (T1D) followed by a 2-year safety follow-up.
- Trial name
- SUNRISE (NCT03895437)
- Testing
- TOL-3021
- Where
- 23 sites in United States
- Volunteers
- 78 people
- Sponsor
- Tolerion, Inc.
Gastric Adenocarcinoma, Advanced Solid Tumors
A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activities of AK104，a PD-1/CTLA-4 bispecific antibody, when administered as a single…
- Conditions
- Gastric Adenocarcinoma, Advanced Solid Tumors, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT03852251
- Testing
- AK104, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 338 people
- Sponsor
- Akeso
Type 1 Diabetes
Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes
This study is a single-arm, multi-center, Home and Hotel Clinical Investigation in subjects with type 1 diabetes on insulin pump therapy.
- Trial name
- NCT02463097
- Testing
- Insulin Pump
- Where
- 10 sites in United States, Israel
- Volunteers
- 124 people
- Sponsor
- Medtronic MiniMed, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.